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Prevention and Control of Influenza 
Recommendations of the Immunization 
Practices Advisory Committee (ACIP)
These recommendations update information on the vaccine and antiviral agents available for 
controlling influenza during the 1990-1991 influenza season (superseding both the MMWR 
1988;37:361-73 on antiviral agents and MMWR 1989;38:297-8, 303-11 on the use of influenza 
vaccine). Changes include statements about a) the influenza strains in the trivalent vaccine for 
1990-1991 and b) revised recommendations for the use of antiviral agents for controlling 
outbreaks of influenza. INTRODUCTION
Influenza A viruses are classified into subtypes on the basis of two surface antigens: 
hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin (HI, H2, H3) and 
two subtypes of neuraminidase (N1, N2) are recognized among influenza A viruses that have 
caused widespread human disease. Immunity to these antigens—especially to the hemagglutinin- 
-reduces the likelihood of infection and lessens the severity of disease if infection occurs. 
Infection with a virus of one subtype confers little or no protection against viruses of other 
subtypes. Furthermore, over time, antigenic variation (antigenic drift) within a subtype may be 
so marked that infection or vaccination with one strain may not induce immunity to distantly 
related strains of the same subtype. Although influenza B viruses have shown more antigenic 
stability than influenza A viruses, antigenic variation does occur. For these reasons, major 
epidemics of respiratory disease caused by new variants of influenza continue to occur. The 
antigenic characteristics of strains currently circulating provide the basis for selecting virus 
strains to include in each year's vaccine.
Typical influenza illness is characterized by abrupt onset of fever, myalgia, sore throat, and 
nonproductive cough. Unlike other common respiratory infections, influenza can cause severe 
malaise lasting several days. More severe illness can result if primary influenza pneumonia or 
secondary bacterial pneumonia occur. During influenza epidemics, high attack rates of acute 
illness result in increased numbers of visits to physicians' offices, walk-in clinics, and 
emergency rooms and increased hospitalizations for management of lower-respiratory-tract 
complications.
Fdderly persons and persons with underlying health problems are at increased risk for 
complications of influenza infection. If infected, such high-risk persons are more likely than the 
general population to require hospitalization. During major epidemics, hospitalization rates for 
high-risk adults may increase two- to fivefold, depending on the age group. Previously healthy 
children and younger adults may also require hospitalization for influenza-related
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complications, but the relative increase in their hospitalization rates is less than for persons who 
belong to high-risk groups.
An increase in mortality further indicates the impact of influenza epidemics. Increased mortality 
results not only from influenza and pneumonia but also from cardiopulmonary and other chronic 
diseases that can be exacerbated by influenza infection. At least 10,000 excess deaths have been 
documented in each of 19 different U.S. epidemics in the period 1957-1986; greater than 40,000 
excess deaths occurred in each of three of these epidemics. Approximately 80%-90% of the 
excess deaths attributed to pneumonia and influenza were among persons greater than or equal 
to 65 years of age.
Because the proportion of elderly persons in the U.S. population is increasing and because age 
and its associated chronic diseases are risk factors for severe influenza illness, the toll from 
influenza can be expected to increase unless control measures are used more vigorously. The 
number of younger persons at increased risk for influenza-related complications is also 
increasing for various reasons, such as the success of neonatal intensive care units, better 
management of diseases such as cystic fibrosis and acquired immunodeficiency syndrome 
(AIDS), and better survival rates for organ-transplant recipients. OPTIONS FOR THE 
CONTROL OF INFLUENZA
Two measures available in the United States that can reduce the impact of influenza are 
immunoprophylaxis with inactivated (killed-virus) vaccine and chemoprophylaxis or therapy 
with an influenza-specific antiviral drug (e.g., amantadine). Vaccination of high-risk persons 
each year before the influenza season is currently the most effective measure for reducing the 
impact of influenza. Vaccination can be highly cost-effective when a) it is directed at persons 
who are most likely to experience complications or who are at increased risk for exposure, and 
b) it is administered to high-risk persons during hospitalization or a routine health-care visit 
before the influenza season, thus making special visits to physicians' offices or clinics 
unnecessary. Recent reports indicate that-when vaccine and epidemic strains of virus are well 
matched—achieving high vaccination rates among closed populations can reduce the risk of 
outbreaks by inducing herd immunity.
Other indications for vaccination include the strong desire of any person to avoid influenza 
infection, reduce the severity of disease, or reduce the chance of transmitting influenza to high- 
risk persons with whom the individual has frequent contact.
The antiviral agent available for use at this time (amantadine hydrochloride) is effective only 
against influenza A and, for maximum effectiveness as prophylaxis, must be used throughout 
the period of risk. When used as either prophylaxis or therapy, the potential effectiveness of 
amantadine must be balanced against potential side effects.
Chemoprophylaxis is not a substitute for vaccination. Recommendations for chemoprophylaxis 
are provided primarily to help health-care providers make decisions regarding persons who are 
at greatest risk of severe illness and complications if infected with an influenza A virus. Use of 
amantadine may be considered a) as a control measure when influenza A outbreaks occur in 
institutions housing high-risk persons, both for treatment of ill individuals and as prophylaxis 
for others; b) as short-term prophylaxis after late vaccination of high-risk individuals (i.e., when 
influenza A infections are already occurring in the community) during the period when 
immunity is developing in response to vaccination; c) as seasonal prophylaxis for individuals 
for whom vaccination is contraindicated; d) as seasonal prophylaxis for immunocompromised 
individuals who may not produce protective levels of antibody in response to vaccination; and
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e) as prophylaxis for unvaccinated health-care workers and household contacts who care for 
high-risk individuals either for the duration of influenza activity in the community or until 
immunity develops after vaccination.
Amantadine is also approved for use by any person who wishes to reduce his or her chances of 
becoming ill with influenza A. INACTIVATED VACCINE FOR INFLUENZA A AND B
Influenza vaccine is made from highly purified, egg-grown viruses that have been rendered 
noninfectious (inactivated). Therefore, the vaccine cannot cause influenza. Each year's influenza 
vaccine contains three virus strains (usually two type A and one type B) representing influenza 
viruses believed likely to circulate in the United States in the upcoming winter. The composition 
of the vaccine is such that it rarely causes systemic or febrile reactions. Whole-virus, subvirion, 
and purified-surface-antigen preparations are available. To minimize febrile reactions, only 
subvirion or purified-surface-antigen preparations should be used for children; any of the 
preparations may be used for adults. Most vaccinated children and young adults develop high 
postvaccination hemagglutination-inhibition antibody titers that are protective against infection 
by strains similar to those in the vaccine or the related variants that may emerge during outbreak 
periods. Elderly persons and persons with certain chronic diseases may develop lower 
postvaccination antibody titers than healthy young adults, and thus may remain susceptible to 
influenza upper-respiratory-tract infection. Nevertheless, even if such persons develop influenza 
illness, the vaccine has been shown to be effective in preventing lower-respiratory-tract 
involvement or other complications, thereby reducing the risk of hospitalization and death. 
RECOMMENDATIONS FOR USE OF INFLUENZA VACCINE
Influenza vaccine is strongly recommended for any person greater than or equal to 6 months of 
age who~because of age or underlying medical condition—is at increased risk for complications 
of influenza. Health-care workers and others (including household members) in close contact 
with high-risk persons should also be vaccinated. In addition, influenza vaccine may be given to 
any person who wishes to reduce the chance of becoming infected with influenza.
The trivalent influenza vaccine prepared for the 1990-1991 season will include A/Taiwan/1/86- 
like (H1N1), A/Shanghai/16/89-like (H3N2), and B/Yamagata/16/88-like hemagglutinin 
antigens. Recommended doses are listed in Table 1. Guidelines for the use of vaccine in 
different groups follow.
Although the current influenza vaccine can contain one or more antigens used in previous years, 
annual vaccination using the current vaccine is necessary because immunity for an individual 
declines in the year following vaccination. Because the 1990-1991 vaccine differs from the 
1989-1990 vaccine, supplies of 1989-1990 vaccine should not be used to provide protection for 
the 1990-1991 influenza season.
Two doses may be required for a satisfactory antibody response in previously unvaccinated 
children less than 9 years of age; however, studies with vaccines similar to those in current use 
have shown little or no improvement in antibody responses when a second dose is given to 
adults during the same season.
During the past decade, data on influenza vaccine immunogenicity and side effects have been 
obtained when vaccine has been administered intramuscularly. Because there has been no 
adequate evaluation o f  recent influenza vaccines administered by other routes, the intramuscular 
route is the one recommended for use. Adults and older children should be vaccinated in the
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deltoid muscle, and infants and young children in the anterolateral aspect of the thigh. TARGET 
GROUPS FOR SPECIAL VACCINATION PROGRAMS
To maximize protection of high-risk persons, they and their close contacts should be targeted 
for organized vaccination programs. Groups at Increased Risk for Influenza-Related 
Complications:
1. Persons greater than or equal to 65 years of age.
2. Residents of nursing homes and other chronic-care
facilities housing persons of any age with chronic medical conditions.
3. Adults and children with chronic disorders of the pulmonary or cardiovascular systems, 
including children with asthma.
4. Adults and children who have required regular medical follow-up or hospitalization during 
the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal 
dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused 
by medications).
5. Children and teenagers (6 months-18 years of age) who are receiving long-term aspirin 
therapy, and therefore may be at risk of developing Reye syndrome after influenza. Groups That 
Can Transmit Influenza to High-Risk Persons:
Persons who are clinically or subclinically infected and who attend or live with high-risk 
persons can transmit influenza virus to them. Some high-risk persons (e.g., the elderly, 
transplant recipients, or persons with AIDS) can have low antibody responses to influenza 
vaccine. Efforts to protect these high-risk persons against influenza may be improved by 
reducing the chances of exposure to influenza from their care providers. Therefore, the 
following groups should be vaccinated:
1. Physicians, nurses, and other personnel in both hospital
and outpatient-care settings who have contact with high-risk persons in all age groups, including 
infants.
2. Employees of nursing homes and chronic-care facilities who have contact with patients or 
residents.
3. Providers of home care to high-risk persons (e.g., visiting nurses, volunteer workers).
4. Household members (including children) of high-risk persons.
VACCINATION OF OTHER GROUPS General Population
Physicians should administer influenza vaccine to any person who wishes to reduce the chance 
of acquiring influenza infection. Persons who provide essential community services and 
students or other persons in institutional settings (e.g., schools and colleges) may be considered 
for vaccination to minimize the disruption of routine activities during outbreaks. Pregnant
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Women
Influenza-associated excess mortality among pregnant women has not been documented except 
in the pandemics of 1918-1919 and 1957-1958. However, pregnant women who have other 
medical conditions that increase their risks for complications from influenza should be 
vaccinated, as the vaccine is considered safe for pregnant women. Administering the vaccine 
after the first trimester is a reasonable precaution to minimize any concern over the theoretical 
risk of teratogenicity. However, it is undesirable to delay vaccination of pregnant women who 
have high-risk conditions and who will still be in the first trimester of pregnancy when the 
influenza season begins. Persons Infected with HIV
Little information exists regarding the frequency and severity of influenza illness in human 
immunodeficiency virus(HIV)-infected persons, but recent reports suggest that symptoms may 
be prolonged and the risk of complications increased for this high-risk group. Because influenza 
may result in serious illness and complications, vaccination is a prudent precaution and will 
result in protective antibody levels in many recipients. However, the antibody response to 
vaccine may be low in persons with advanced HIV-related illnesses; a booster dose of vaccine 
has not improved the immune response for these individuals. Foreign Travelers
Increasingly, the elderly and persons with high-risk medical conditions are embarking on 
international travel. The risk of exposure to influenza during foreign travel varies, depending on 
season and destination. In the tropics, influenza can occur throughout the year; in the southern 
hemisphere, the season of greatest activity is April-September. Because of the short incubation 
period for influenza, exposure to the virus during travel can result in clinical illness that also 
begins while traveling, an inconvenience or potential danger, especially for persons at increased 
risk for complications. Persons preparing to travel to the tropics at any time of year or to the 
southern hemisphere during April-September should review their influenza vaccination 
histories. If they were not vaccinated the previous fall/winter, they should consider influenza 
vaccination before travel. Persons in the high-risk categories should be especially encouraged to 
receive the most currently available vaccine. High-risk persons given the previous season's 
vaccine before travel should be revaccinated in the fall/winter with current vaccine. PERSONS 
WHO SHOULD NOT BE VACCINATED
Inactivated influenza vaccine should not be given to persons known to have anaphylactic 
hypersensitivity to eggs (see "Side Effects and Adverse Reactions").
Persons with acute febrile illnesses usually should not be vaccinated until their symptoms have 
abated. SIDE EFFECTS AND ADVERSE REACTIONS
Because influenza vaccine contains only noninfectious viruses, it cannot cause influenza. 
Respiratory disease after vaccination represents coincidental illness unrelated to influenza 
vaccination. The most frequent side effect of vaccination is soreness at the vaccination site that 
lasts for up to 2 days; this is reported for less than one-third of vaccinees.
In addition, two types of systemic reactions have occurred:
1. Fever, malaise, myalgia, and other systemic symptoms occur
infrequently and most often affect persons who have had no exposure to the influenza virus 
antigens in the vaccine (e.g., young children). These reactions begin 6-12 hours after
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vaccination and can persist for 1 or 2 days.
2. Immediate—presumably allergic—reactions (such as hives, angioedema, allergic asthma, or 
systemic anaphylaxis) occur rarely after influenza vaccination. These reactions probably result 
from hypersensitivity to some vaccine component—most likely residual egg protein. Although 
current influenza vaccines contain only a small quantity of egg protein, this protein presumably 
induces immediate hypersensitivity reactions in persons with severe egg allergy. Persons who 
have developed hives, have had swelling of the lips or tongue, or experienced acute respiratory 
distress or collapse after eating eggs should not be given the influenza vaccine. Persons with 
documented immunoglobulin E(IgE)-mediated hypersensitivity to eggs—including those who 
have had occupational asthma or other allergic responses from exposure to egg protein—may 
also be at increased risk for reactions from influenza vaccine. The protocol for influenza 
vaccination developed by Murphy and Strunk may be considered for patients who have egg 
allergies and medical conditions that place them at increased risk for influenza infection or its 
complications (See Murphy and Strunk, 1985).
Unlike the 1976 swine influenza vaccine, subsequent vaccines prepared from other virus strains 
have not been associated with an increased frequency of Guillain-Barre syndrome. Although 
influenza vaccination can inhibit the clearance of warfarin and theophylline, studies have failed 
to show any adverse clinical effects attributable to these drugs in patients receiving influenza 
vaccine. SIMULTANEOUS ADMINISTRATION OF OTHER VACCINES, INCLUDING 
CHILDHOOD VACCINES
The target groups for influenza and pneumococcal vaccination overlap considerably. Both 
vaccines can be given at the same time at different sites without increasing side effects. 
However, influenza vaccine must be given each year; with few exceptions, pneumococcal 
vaccine should be given only once.
High-risk children may receive influenza vaccine at the same time as measles-mumps-rubella, 
Haemophilus b, pneumococcal, and oral polio vaccines. Vaccines should be given at different 
sites. Influenza vaccine should not be given within 3 days of vaccination with pertussis vaccine. 
TIMING OF INFLUENZA VACCINATION ACTIVITIES
Beginning each September, when vaccine for the upcoming influenza season becomes available, 
high-risk persons who are hospitalized or who are seen by health-care providers for routine care 
should be offered influenza vaccine. Except in years of pandemic influenza (e.g., 1957 and 
1968), high levels of influenza activity rarely occur in the contiguous 48 states before 
December. Therefore, November is the optimal time for organized vaccination campaigns for 
high-risk persons. In facilities such as nursing homes, it is particularly important to avoid 
administering vaccine too far in advance of the influenza season because antibody levels begin 
declining within a few months. Vaccination programs may be undertaken as soon as current 
vaccine is available if regional influenza activity is expected to begin earlier than December.
Children less than 9 years of age who have not previously been vaccinated should receive two 
doses of vaccine at least a month apart to maximize the chance of a satisfactory antibody 
response to all three vaccine antigens. The second dose should be given before December, if 
possible. Vaccine should be offered to both children and adults up to and even after influenza 
virus activity is documented in a community, as late as April in some years. STRATEGIES 
FOR IMPLEMENTING INFLUENZA VACCINE RECOMMENDATIONS
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Despite the recognition that optimum medical care for both adults and children includes regular 
review of immunization records and administration of vaccines as appropriate, less than 30% of 
persons in high-risk groups receive influenza vaccine each year. More effective strategies are 
needed for delivering vaccine to high-risk persons, their health-care providers, and their 
household contacts.
In general, successful vaccination programs have combined education for health-care workers, 
publicity and education targeted toward potential recipients, a plan for identifying (usually by 
medical-record review) persons at high-risk, and efforts to remove administrative and financial 
barriers that prevent persons from receiving the vaccine.
Persons for whom influenza vaccine is recommended can be identified and vaccinated in the 
settings described below. Outpatient Clinics and Physicians' Offices
Staff in physicians' offices, clinics, health-maintenance organizations, and employee health 
clinics should be instructed to identify and label the medical records of patients who should 
receive vaccine. Vaccine should be offered during visits beginning in September and throughout 
the influenza season. Offer of vaccine and its receipt or refusal should be documented in the 
medical record. Patients in high-risk groups who do not have regularly scheduled visits during 
the fall should be reminded by mail or telephone of the need for vaccine. If possible, 
arrangements should be made to provide vaccine with minimal waiting time and at the lowest 
possible cost. Facilities Providing Episodic or Acute Care (e.g., emergency rooms, walk-in 
clinics)
Health-care providers in these settings should be familiar with influenza vaccine 
recommendations and should offer vaccine to persons in high-risk groups or should provide 
written information on why, where, and how to obtain the vaccine. Written information should 
be available in language(s) appropriate for the population served by the facility. Nursing Homes 
and Other Residential Long-Term-Care Facilities
Vaccination should be routinely provided to all residents of chronic-care facilities with the 
concurrence of attending physicians rather than by obtaining individual vaccination orders for 
each patient. Consent for vaccination should be obtained from the resident or a family member 
at the time of admission to the facility, and all residents should be vaccinated at one time 
immediately preceding the influenza season. Residents admitted during the winter months after 
completion of the vaccination program should be vaccinated when they are admitted. Acute- 
Care Hospitals
All persons greater than or equal to 65 years of age and younger persons (including children) 
with high-risk conditions who are hospitalized from September through March should be 
offered and strongly encouraged to receive influenza vaccine before they are discharged. 
Household members and others with whom they will have contact should receive written 
information about why and where to obtain influenza vaccine. Outpatient Facilities Providing 
Continuing Care to High-Risk Patients (e.g., hemodialysis centers, hospital specialty-care 
clinics, outpatient rehabilitation programs)
All patients should be offered vaccine in one period shortly before the beginning of the 
influenza season. Patients admitted to such programs during the winter months after the earlier 
vaccination program has been conducted should be vaccinated at the time of admission.
Household members should receive written information regarding the need for vaccination and
http://www.cdc.gOv/mmwr//preview/mmwrhtml/00001644.htm 3/31/2009
Prevention and Control of Influenza Recommendations of the Immunization Practices Ad... Page 8 of 15
the places to obtain influenza vaccine. Visiting Nurses and Others Providing Home Care to 
High-Risk Persons
Nursing-care plans should identify high-risk patients, and vaccine should be provided in the 
home if necessary. Care givers and others in the household (including children) should be 
referred for vaccination. Facilities Providing Services to Persons greater than or equal to 65 
Years of Age (e.g., retirement communities, recreation centers)
All unvaccinated residents/attendees should be offered vaccine on site at one time period before 
the influenza season; alternatively, education/publicity programs should emphasize the need for 
influenza vaccine and should provide specific information on how, where, and when to obtain it. 
Clinics and Others Providing Health Care for Travelers
Indications for influenza vaccination should be reviewed before travel and vaccine offered if 
appropriate (see "Foreign Travelers"). Health-Care Workers
Administrators of all health-care facilities should arrange for influenza vaccine to be offered to 
all personnel before the influenza season. Personnel should be provided with appropriate 
educational materials and strongly encouraged to receive vaccine, with particular emphasis on 
vaccination of persons who care for high-risk patients (e.g., staff of intensive-care units, 
including newborn intensive-care units; staff of medical/surgical units; and employees of 
nursing homes and chronic-care facilities). Using a mobile cart to take vaccine to hospital wards 
or other work sites and making vaccine available during night and weekend work shifts may 
enhance compliance, as may a follow-up campaign if an outbreak occurs in the community. 
ANTIVIRAL AGENTS FOR INFLUENZA A
The two antiviral agents with specific activity against influenza A viruses are amantadine 
hydrochloride and rimantadine hydrochloride. Only amantadine islicensed for use in the United 
States. These chemically related drugs interfere with the replication cycle of type A (but not 
type B) influenza viruses, although the specific mechanisms of their antiviral activity are not 
completely understood. When given prophylactically to healthy young adults or children in 
advance of and throughout the epidemic period, amantadine is approximately 70%-90% 
effective in preventing illnesses caused by naturally occurring strains of type A influenza 
viruses. When administered to otherwise healthy young adults and children for symptomatic 
treatment within 48 hours after the onset of influenza illness, amantadine has been shown to 
reduce the duration of fever and other systemic symptoms and may permit a more rapid return 
to routine daily activities. Since antiviral agents taken prophylactically may prevent illness but 
not subclinical infection, some persons who take these drugs may still develop immune 
responses that will protect them when exposed to antigenically related viruses in later years.
As with all drugs, symptoms may occur that are side effects of amantadine in a small proportion 
of persons. Such symptoms are rarely severe, but may be important for some categories of 
patients. RECOMMENDATIONS FOR THE USE OF AMANTADINE Outbreak Control in 
Institutions
When outbreaks of influenza A occur in institutions that house high-risk persons, 
chemoprophylaxis should begin as early as possible to reduce the spread of the infection. 
Contingency planning is needed to ensure rapid administration of amantadine to residents and 
employees. This should include preapproved medication orders or plans to obtain physicians' 
orders on short notice. When amantadine is used for outbreak control, it should be administered
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to all residents of the affected institution regardless of whether they received influenza vaccine 
the previous fall. The dose for each resident should be determined after consulting the dosage 
recommendations and precautions that follow in this document and those listed in the 
manufacturer's package insert. To reduce spread of virus and to minimize disruption of patient 
care, chemoprophylaxis should also be offered to unvaccinated staff who provide care to high- 
risk patients. To be fully effective as prophylaxis, the antiviral drug must be taken each day for 
the duration of influenza activity in the community. Use as Prophylaxis High-risk individuals 
vaccinated after influenza A activity has begun
High-risk individuals can still be vaccinated after an outbreak of influenza A has begun in a 
community. However, the development of antibodies in adults after vaccination usually takes 2 
weeks, during which time amantadine should be given. Children who receive influenza vaccine 
for the first time may require up to 6 weeks of prophylaxis, or until 2 weeks after the second 
dose of vaccine has been received. Amantadine does not interfere with the antibody response to 
the vaccine. Persons providing care to high-risk persons
To reduce the spread of virus and to maintain care for high-risk persons in the home, hospital, or 
institutional setting, chemoprophylaxis should be considered for unvaccinated persons who have 
frequent contact with high-risk persons in the home setting (e.g., household members, visiting 
nurses, volunteer workers) and unvaccinated employees of hospitals, clinics, and chronic-care 
facilities. For employees who cannot be vaccinated, chemoprophylaxis should be continued for 
the entire period influenza A virus is circulating in the community; for those who are vaccinated 
at a time when influenza A is present in the community, chemoprophylaxis should be given for 
2 weeks after vaccination. Prophylaxis should be considered for all employees, regardless of 
their vaccination status, if the outbreak is caused by a variant strain of influenza A that is not 
covered by the vaccine. Immunodeficient persons
Chemoprophylaxis may be indicated for high-risk patients who are expected to have a poor 
antibody response to influenza vaccine. This includes many persons with HIV infection, 
especially those with advanced disease. No data are available on possible interactions with other 
drugs used in the management of patients with HIV infection. Such patients must be monitored 
closely if amantadine is used. Persons for whom influenza vaccine is contraindicated
Chemoprophylaxis throughout the influenza season may be appropriate for high-risk persons for 
whom influenza vaccine is contraindicated because of anaphylactic hypersensitivity to egg 
protein. Other persons
Amantadine can also be used prophylactically by anyone who wishes to avoid influenza A 
illness. This decision should be made by the physician and patient on an individual basis. Use as 
Therapy
Although amantadine can reduce the severity and shorten the duration of influenza A illness in 
healthy adults, there are no data on the efficacy of amantadine therapy in preventing 
complications of influenza A in high-risk persons. Therefore, no specific recommendations can 
be made regarding the therapeutic use of amantadine for these patients. This does not preclude 
physicians from using amantadine in high-risk patients who develop illness compatible with 
influenza during a period of known or suspected influenza A activity in the community.
Whether amantadine is effective when treatment begins beyond the first 48 hours of illness is 
not known. OTHER CONSIDERATIONS FOR THE SELECTION OF AMANTADINE FOR 
PROPHYLAXIS OR TREATMENT Side Effects/Toxicity
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When amantadine is administered to healthy young adults at a dose of 200 mg divided by ay, 
minor central-nervous-system (CNS) side effects (nervousness, anxiety, insomnia, difficulty 
concentrating, and lightheadedness) and/or gastrointestinal side effects (anorexia and nausea) 
occur in approximately 5%-10% of patients. Side effects diminish or cease soon after 
discontinuing use of the drug. With prolonged use, side effects may also diminish or disappear 
after the first week of use. More serious but less frequent CNS-related side effects (seizures, 
confusion) associated with use of amantadine have usually affected only elderly persons, those 
with renal disease, and those with seizure disorders or other altered mental/behavioral 
conditions. Reducing the dosage to less than or equal to 100 mg divided by ay appears to reduce 
the frequency of these side effects in such persons without compromising the prophylactic 
effectiveness of amantadine.
The package insert should be consulted before use of amantadine for any patient. The patient's 
age, weight, renal function, presence of other medical conditions, and indications for use of 
amantadine (prophylaxis or therapy) must be considered, and the dosage and duration of 
treatment adjusted appropriately. Modifications in dosage may be required for persons with 
impaired renal function, the elderly, children, persons who have neuropsychiatric disorders or 
who take psychotropic drugs, and persons with a history of seizures. Development of Drug- 
Resistant Viruses
Amantadine-resistant influenza viruses can emerge when amantadine is used for treatment. The 
frequency with which resistant isolates emerge and the extent of their transmission are 
unknown, but there is no evidence that amantadine-resistant viruses are more virulent or more 
transmissible than amantadine-sensitive viruses. Thus the use of amantadine remains an 
appropriate outbreak control measure. In closed populations such as nursing homes, persons 
with influenza who are treated with amantadine should be separated, if possible, from 
asymptomatic persons who are given amantadine as prophylaxis. Because of possible induction 
of amantadine resistance, it is advisable to discontinue amantadine treatment of persons who 
have influenza-like illness as soon as clinically warranted, generally within 3-5 days. Isolation 
of influenza viruses from persons who are receiving amantadine should be reported through 
state health departments to CDC and the isolates saved for antiviral sensitivity testing.
SOURCES OF INFORMATION ON INFLUENZA-CONTROL PROGRAMS
Educational materials about influenza and its control are available from several sources, 
including CDC. Information can be obtained from Technical Information Services, Center for 
Prevention Services, Mailstop E06, CDC, Atlanta, GA 30333. Phone number: (404) 639-1819. 
State and local health departments should also be consulted regarding availability of vaccine 
and access to vaccination programs. Selected Bibliography GENERAL
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